InnoCan Pharma Corporation
INNPF
$0.14
$0.0086.06%
OTC PK
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -37.37% | -0.23% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -37.37% | -0.23% | |||
| Cost of Revenue | 17.40% | 30.80% | |||
| Gross Profit | -43.32% | -2.74% | |||
| SG&A Expenses | -29.01% | 0.13% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -23.60% | 1.97% | |||
| Operating Income | -361.08% | -33.83% | |||
| Income Before Tax | -99.57% | -51.05% | |||
| Income Tax Expenses | -87.80% | -12.55% | |||
| Earnings from Continuing Operations | -116.90% | -70.29% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 88.50% | 7.27% | |||
| Net Income | 60.69% | -186.05% | |||
| EBIT | -361.08% | -33.83% | |||
| EBITDA | -352.91% | -33.39% | |||
| EPS Basic | 60.00% | -183.33% | |||
| Normalized Basic EPS | 60.00% | -150.00% | |||
| EPS Diluted | 60.00% | -200.00% | |||
| Normalized Diluted EPS | 60.00% | -150.00% | |||
| Average Basic Shares Outstanding | 1.91% | 0.35% | |||
| Average Diluted Shares Outstanding | 1.91% | 0.35% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||